证券研究报告 | 2025年06月22日 医药生物周报（25 年第 24 周） 优于大市 政策出台加速+AI 应用落地有望带来医疗服务行业新增长 本周医药板块表现强于整体市场，生物医药板块领涨。本周全部 A 股下跌 0.21%（总市值加权平均），沪深 300 下跌 0.25%，中小板指下跌 0.65%， 创业板指上涨 0.22%，生物医药板块整体上涨 1.40%，生物医药板块表 现强于整体市场。分子板块来看，化学制药上涨 3.53%，生物制品上涨 0.33%，医疗服务上涨 2.42%，医疗器械下跌 0.52%，医药商业下跌 0.83%，中药下跌 0.32%。医药板块当前市盈率（TTM）为 34.88x，处 于近 5 年历史估值的 74.55%分位数。 生育津贴政策持续推进完善，催生辅助生殖需求提升。自政府工作报告提 出支持生育意愿以来，多地陆续推出生育利好政策，如呼和浩特市为生 育一孩、二孩、三孩分别提供 1 万、5 万、10 万元补贴。目前，全国超 过 20 个省份已实施生育补贴制度，包括现金、购房补贴和育儿假等。 政策的落地推动了生育意愿提升，同时辅助生殖纳入医保也促进了 IVF 渗透率的增长。近 30 ...

"公司发展一直是内生生长和外延并购双轮驱动的，未来公司将以内生生长为主，并购基金已基本完成 历史使命。"5月20日，爱尔眼科医院集团股份有限公司（以下简称"爱尔眼科"）董事长陈邦在2024年年 度股东大会上表示，公司将持续推进"1+8+N"战略，并将在今年制定人工智能发展规划，加速AI赋能眼 科医疗。 2024年，在眼科行业净利普遍下滑的背景下，爱尔眼科仍交出了一份营收、净利润双增长的答卷。报告 期内，公司实现营业收入209.83亿元，同比增长3.02%；归母净利润突破35亿元大关，同比增长5.87%。 同时，公司以每10股派发1.6元（含税）的分红方案持续回馈投资者，派现额度高达14.87亿元。 2025年一季度，爱尔眼科重回高增长轨道，报告期内，实现营业收入60.26亿元，同比增长15.97%；归 母净利润10.5亿元，同比增长16.71%。 "1+8+N"战略落地见效 2024年，爱尔眼科"1+8+N"战略全面落地见效。作为集团战略支点的长沙医学中心持续发挥标杆作用， 八大区域眼科中心建设取得突破性进展——上海、南宁两地旗舰医院率先完成建设任务，湖北、安徽、 沈阳、贵州四区域中心相继投入运营，形成辐射全 ...

Group 1: Company Insights - The company achieved a revenue of 11.36 billion yuan in Q1 2025, representing a year-on-year increase of 22.47% and a quarter-on-quarter increase of 29.43% [5] - The net profit attributable to shareholders for Q1 2025 was 2.83 billion yuan, up 11.82% year-on-year, while the non-recurring net profit was 2.75 billion yuan, reflecting a year-on-year increase of 38.71% [5] - The newly launched game "Wanjian Changsheng" contributed significantly to revenue and profit growth in Q1 2025, with a revenue of 3.63 billion yuan [6] Group 2: Industry Trends - The eye care industry is experiencing a slowdown in growth, with the company managing to maintain revenue growth despite external challenges, achieving a revenue of 60 billion yuan in Q1 2025, up 16% year-on-year [8][9] - The company is expanding its international presence, with significant revenue contributions from Europe and Southeast Asia, achieving a total revenue of 210 billion yuan in 2024 [10] - The chemical industry is seeing a substantial increase in revenue, with the company reporting a revenue of 8.59 billion yuan in Q1 2025, a year-on-year increase of 91.68% [12][15] Group 3: Financial Performance - The company reported a net profit of 0.67 billion yuan in Q1 2025, which is a 10.46% increase year-on-year and a remarkable 902.93% increase quarter-on-quarter [12][15] - The net profit margin for the company improved significantly, with a sales net profit margin of 10.80% in Q1 2025, reflecting a year-on-year decrease of 3.1 percentage points [12] - The company is expected to see continued revenue growth, with projected revenues of 41.27 billion yuan, 48.48 billion yuan, and 55.70 billion yuan for 2025, 2026, and 2027 respectively [17]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][7][8] Core Insights - The company reported a revenue of 21 billion yuan in 2024, representing a 3% year-on-year increase, and a net profit of 3.56 billion yuan, up 6% year-on-year. In Q1 2025, the company achieved a revenue of 6 billion yuan, a 16% increase, and a net profit of 1.05 billion yuan, a 17% increase [2][4] - The company is focusing on the "AI + Ophthalmology" strategy, enhancing its digital capabilities and expanding its international presence, particularly in Europe [4][5] - The company has maintained growth in patient volume despite a slowing industry, with outpatient visits increasing by 12% and surgeries by 9% in 2024 [4][5] Financial Performance - The company is projected to achieve revenues of 23.75 billion yuan, 26.84 billion yuan, and 30.34 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 13.2%, 13.0%, and 13.0% [6][7] - The net profit is expected to reach 4.17 billion yuan, 4.88 billion yuan, and 5.71 billion yuan for the same years, with growth rates of 17.2%, 17.1%, and 17.0% respectively [6][7] - The company maintains a strong return on equity (ROE) forecasted to increase from 17% in 2024 to 20% in 2027 [6][7][8] Market Performance - The company's stock has shown a performance of -2.7% over the last month, 6.5% over the last three months, and 5.3% over the last year, outperforming the CSI 300 index in the three-month and one-year periods [3][4] - The current stock price is 13.13 yuan, with a 52-week price range of 9.05 to 19.09 yuan [3][4] Strategic Initiatives - The company is advancing its "1+8+N" layout and international strategy, with a total of 352 domestic hospitals and 163 overseas ophthalmology centers and clinics as of December 31, 2024 [4][5] - The introduction of AI technologies, such as AierGPT and Eyecho, aims to enhance patient care and operational efficiency [4][5]